ABIVAX Société Anonyme (EPA: ABVX)
France
· Delayed Price · Currency is EUR
7.85
-0.10 (-1.26%)
Dec 2, 2024, 5:35 PM CET
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 6.79M EUR in the half year ending June 30, 2024, with 204.58% growth. This brings the company's revenue in the last twelve months to 9.03M, up 100.87% year-over-year. In the year 2023, ABIVAX Société Anonyme had annual revenue of 4.49M with 0.38% growth.
Revenue (ttm)
9.03M
Revenue Growth
+100.87%
P/S Ratio
49.18
Revenue / Employee
145.66K
Employees
61
Market Cap
497.19M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.49M | 17.00K | 0.38% |
Dec 31, 2022 | 4.48M | 273.00K | 6.50% |
Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
Dec 31, 2020 | 14.00K | 21.00K | -300.00% |
Dec 31, 2019 | -7.00K | -822.00K | -100.86% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 48.45B |
EssilorLuxottica Société anonyme | 25.83B |
Sartorius Stedim Biotech S.A. | 2.74B |
bioMérieux S.A. | 3.81B |
Ipsen S.A. | 3.44B |
Eurofins Scientific SE | 6.72B |
Virbac SA | 1.34B |
Ramsay Générale de Santé SA | 5.01B |
ABIVAX Société Anonyme News
- 13 days ago - Abivax Establishes an At-the-Market (ATM) Program on Nasdaq - GlobeNewsWire
- 18 days ago - Abivax reports liqyuduty position - Seeking Alpha
- 18 days ago - Abivax presents third quarter 2024 key financial information - GlobeNewsWire
- 19 days ago - Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax - GlobeNewsWire
- 2 months ago - Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - GlobeNewsWire
- 2 months ago - Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease - GlobeNewsWire
- 2 months ago - Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance - GlobeNewsWire
- 2 months ago - Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 - GlobeNewsWire